ERBB3 and non-small cell lung carcinoma: The phase 1 HER3-DXd study in NSCLC patients has an ORR of 36.4% in patients with brain metastasis and a median DOR of 7.3 months, suggesting some activity, but more work needs to be done, particularly given the high risk of CNS metastasis in these patients (72).